Fredag 27 December | 07:38:23 Europe / Stockholm

Prenumeration

Kalender

Tid*
2026-01-14 N/A Årsstämma
2026-01-14 N/A Kvartalsrapport 2026-Q1
2025-10-29 N/A Bokslutskommuniké 2025
2025-07-09 N/A Kvartalsrapport 2025-Q3
2025-04-09 N/A Kvartalsrapport 2025-Q2
2025-01-24 N/A Kvartalsrapport 2025-Q1
2025-01-16 N/A X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15 N/A Årsstämma
2024-10-23 - Bokslutskommuniké 2024
2024-07-31 - Extra Bolagsstämma 2024
2024-07-10 - Kvartalsrapport 2024-Q3
2024-04-10 - Kvartalsrapport 2024-Q2
2024-01-11 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 - Årsstämma
2024-01-10 - Kvartalsrapport 2024-Q1
2023-10-11 - Bokslutskommuniké 2023
2023-07-14 - Kvartalsrapport 2023-Q3
2023-04-12 - Kvartalsrapport 2023-Q2
2023-01-12 - X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 - Årsstämma
2023-01-11 - Kvartalsrapport 2023-Q1
2022-10-13 - Bokslutskommuniké 2022
2022-07-06 - Kvartalsrapport 2022-Q3
2022-04-13 - Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
2024-01-10 11:20:00

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 10 January 2024. At the meeting 10 771 741 shares were represented, which corresponds to approx. 55 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.

Allocation of the company’s result
The AGM resolved to adopt the income statement and balance sheet for the company as well as the consolidated income statement and consolidated balance sheet for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

The AGM approved the board’s proposal that the result should be carried forward.

Fees to the board members and the auditors
The AGM agreed on the following fees to the board and the auditors.

Each one of the board members elected by the AGM (and who are not employed in the group) – 60,000 SEK

Fees to the auditors shall be paid in accordance with approved invoices.

Board members, chairman of the board and auditors
Karl Karlsson, Andreas Hedskog, Anil Okay and Johan Strömqvist were re-elected as board members. Karl Karlsson was re-elected as chairman of the board.

Ernst & Young AB was elected as the company’s auditor, with Martin Henriksson as auditor in charge.

Authorization for the board to decide on issue of new shares
The AGM resolved to authorize the board of Newbury Pharmaceuticals AB to decide to issue new shares in the company, in accordance with the board’s proposal.